Gilde Healthcare Private Equity IV launches €517m
Gilde Healthcare Private Equity IV (GHPE IV) has closed at €517m for investments in proifitable healthcare companies in the lower mid-market in North-west Europe.
The new oversubscribed fund will focus its investements on firms with an active buy-and-build strategy and is designed to invest in all sub-segments of the healthcare sector. These include companies in healthcare provision, service providers to the healthcare sector and medical industry, manufacturers of medical supplies and pharmaceutical companies. According to the Utrecht-headquartered equity firm, institutional investors came from the Netherlands, Germany, United Kingdom, France, Italy, and Scandinavia.
With the new fund, we will expand our portfolio with differentiating European growth platforms in the healthcare sector," said Jasper van Gorp, Managing Partner at Gilde Healthcare and Head of the Private Equity team. Gildes pipeline comprises several attractive new investments in North-west Europe.
In combination with its vintage 2020 transatlantic Venture&Growth fund V, Gilde Healthcare has raised €933m in capital in less than two years. In the past fifteen years, Gilde Healthcare has made 70 platform investments, of which 46 have been sold or floated.
Recent examples of private equity investments in healthcare include among others the buy-and-builds of Dutch ACE Pharmaceuticals, German cannula manufacturer Acti-Med, Danish clinical research organization Klifo and Dutch contract research organization Symeres, which was recently sold after a successfully executed international expansion strategy in a three-year timeframe.
Biocytogen Co Ltd
Draupnir Bio ApS